{"nctId":"NCT00235872","briefTitle":"Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis","startDateStruct":{"date":"2004-08"},"conditions":["Rheumatoid Arthritis"],"count":309,"armGroups":[{"label":"Adalimumab 40 mg every other week (eow)","type":"EXPERIMENTAL","interventionNames":["Biological: adalimumab"]}],"interventions":[{"name":"adalimumab","otherNames":["ABT-D2E7","Humira"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participation and completion until Week 24 of the prior adalimumab dose-ranging study.\n* Females must be postmenopausal for at least 1 year, surgically sterile, or practicing birth control throughout the study and for 90 days after study completion.\n* Female subjects tested negative in pregnancy test (serum test) at Week 24 in prior adalimumab study, if capable of pregnancy.\n\nExclusion Criteria:\n\n* A subject who experienced any of the following during prior study:\n\n  * Advanced or poorly controlled diabetes\n  * Joint surgery (joint evaluated in this study)\n* A subject who has been prescribed excluded medications during prior study.\n* History of following during prior study:\n\n  * Clinically significant drug or alcohol abuse\n  * Intravenous (iv) drug abuse\n  * Active infection with listeria or tuberculosis (TB)\n  * Lymphoma, leukemia\n  * And, any malignancy with the exception of successfully treated non-metastatic basal cell carcinoma of the skin.\n* A subject who has been administered a live vaccine during prior study, or subject scheduled to complete the administration of a live vaccine during the study period","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects With American College of Rheumatology (ACR) Criteria Improvement Consisting of 20%, 50%, and 70% (ACR20/50/70 Responders, Respectively)","description":"Number of responders with ACR criteria improvement consisting of 20%, 50%, and 70% (ACR20/50/70, respectively) reduction in tender or swollen joint counts (TJC or SJC, respectively) and 20%, 50%, and 70% improvement, respectively, in 3 of the following 5 criteria: 1) physician's global assessment of disease activity (PGA), 2) subject's assessment of disease activity, 3) subject's assessment of pain, 4) subject's assessment of functional disability via a health assessment questionnaire (DI-HAQ), and 5) C-reactive protein (CRP) at each visit.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"104","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"157","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"154","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"154","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"148","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"155","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"155","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"163","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"158","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"141","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"118","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"166","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"104","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Tender Joint Count (TJC, Max=68), a Component of the American College of Rheumatology (ACR) by Visit","description":"Mean change from Baseline in TJC (max=68) at each visit, a component of ACR. For M02-575 completers, the Baseline for all efficacy analyses was defined as the Week 0 \\[before dosing\\] of the M02-575 study; for the M02-575 rescue arm, the Baseline was defined as the Week 0 \\[before dosing\\] of the M03-651 study.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.3","spread":"11.59"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.2","spread":"10.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.0","spread":"10.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.6","spread":"10.37"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.0","spread":"10.70"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.5","spread":"10.88"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.3","spread":"10.84"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.3","spread":"10.72"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.3","spread":"10.43"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.9","spread":"10.88"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.4","spread":"10.75"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.9","spread":"10.86"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.0","spread":"10.27"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.0","spread":"9.74"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.0","spread":"9.49"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.9","spread":"9.42"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.1","spread":"10.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.4","spread":"10.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.2","spread":"11.63"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-17.7","spread":"10.43"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-17.7","spread":"11.39"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-17.8","spread":"11.75"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-22.4","spread":"8.50"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-24.0","spread":"0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.5","spread":"12.36"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Swollen Joint Count (SJC, Max=66), a Component of the American College of Rheumatology (ACR) by Visit","description":"Mean change from Baseline in SJC (max=66) at each visit, a component of ACR. For M02-575 completers, the Baseline for all efficacy analyses was defined as the Week 0 (before dosing)\\] of the M02-575 study; for the M02-575 rescue arm, the baseline was defined as the Week 0 (before dosing) of the M03-651 study.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.6","spread":"8.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.1","spread":"7.69"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.5","spread":"7.72"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.6","spread":"8.31"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.0","spread":"8.09"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.0","spread":"8.08"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.1","spread":"7.88"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.9","spread":"7.91"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.7","spread":"7.83"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.9","spread":"8.20"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.2","spread":"8.50"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.8","spread":"8.20"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.7","spread":"7.73"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.6","spread":"7.50"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.5","spread":"7.68"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.8","spread":"7.75"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.8","spread":"8.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.3","spread":"7.44"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.0","spread":"7.76"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.7","spread":"7.89"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.3","spread":"7.76"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-17.5","spread":"8.30"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-20.0","spread":"4.97"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-86.0","spread":"0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.6","spread":"8.93"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Physician Global Assessment of Disease Activity (PGA), a Component of the ACR Criteria by Visit","description":"Change from Baseline in PGA (a visual analog scale from 0-100 mm, with 0 being the absence of disease activity and 100 mm being very strong disease activity, a component of the ACR criteria by visit). For M02-575 completers, the Baseline for all efficacy analyses was defined as the Week 0 (before dosing) of the M02-575 study; for the M02-575 rescue arm, the Baseline was defined as the Week 0 (before dosing) of the M03-651 study.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67.2","spread":"19.67"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-20.0","spread":"25.83"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-27.9","spread":"25.80"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-28.1","spread":"26.69"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-28.3","spread":"26.54"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-29.9","spread":"26.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-33.1","spread":"25.59"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-35.1","spread":"25.85"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-37.3","spread":"24.76"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-37.8","spread":"25.08"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-38.1","spread":"25.75"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-39.6","spread":"24.97"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-43.1","spread":"23.43"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-42.8","spread":"22.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-43.6","spread":"23.47"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-42.2","spread":"24.68"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-42.9","spread":"24.79"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-42.3","spread":"23.80"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-44.3","spread":"23.73"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-45.6","spread":"23.23"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-45.0","spread":"26.12"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-46.1","spread":"26.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-60.1","spread":"15.52"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-64.0","spread":"0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-30.2","spread":"30.04"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Subject's Global Assessment of Disease Activity Using a Visual Analog Scale, a Component of the ACR Criteria by Visit","description":"Change from Baseline in Subject's Global Assessment of Disease Activity (a visual analog scale from 0-100 mm (0 being absence of disease activity and 100 being very strong disease activity), a component of the ACR criteria by visit). For M02-575 completers, the Baseline for all efficacy analyses was defined as the Week 0 (before dosing) of the M02-575 study; for the M02-575 rescue arm, the Baseline was defined as the Week 0 (before dosing) of the M03-651 study.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63.5","spread":"24.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.2","spread":"26.93"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-19.4","spread":"28.30"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-19.8","spread":"28.22"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-21.1","spread":"28.62"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-21.0","spread":"28.63"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-23.0","spread":"29.14"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-23.9","spread":"29.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-26.9","spread":"29.38"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-27.3","spread":"28.77"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-28.2","spread":"29.86"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-29.4","spread":"27.90"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-30.4","spread":"29.49"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-31.7","spread":"25.73"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-28.0","spread":"27.73"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-27.9","spread":"26.64"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-29.2","spread":"27.73"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-28.6","spread":"29.54"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-29.7","spread":"28.72"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-29.7","spread":"30.14"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-30.1","spread":"30.45"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-22.3","spread":"32.92"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-48.1","spread":"30.98"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-85.0","spread":"0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-20.7","spread":"31.77"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Subject's Assessment of Pain Using a Visual Analog Scale, a Component of the ACR Criteria by Visit","description":"Change from Baseline in subject's assessment of pain (a visual analog scale from 0-100 mm \\[0 being no pain and 100 being unbearable pain\\], a component of the ACR criteria by visit). For M02-575 completers, the Baseline for all efficacy analyses was defined as the Week 0 (before dosing) of the M02-575 study; for the M02-575 rescue arm, the Baseline was defined as the Week 0 (before dosing) of the M03-651 study.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61.3","spread":"24.03"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.3","spread":"27.64"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-17.0","spread":"28.65"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-17.7","spread":"27.78"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-19.1","spread":"27.66"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-19.6","spread":"27.42"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-22.2","spread":"27.87"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-22.7","spread":"27.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-26.0","spread":"27.55"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-26.5","spread":"28.11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-27.1","spread":"28.53"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-28.6","spread":"26.56"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-28.1","spread":"28.65"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-30.0","spread":"24.27"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-28.6","spread":"24.40"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-26.3","spread":"25.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-28.5","spread":"27.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-27.6","spread":"27.98"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-29.7","spread":"26.65"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-29.4","spread":"27.62"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-29.9","spread":"25.63"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-23.5","spread":"29.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-39.7","spread":"30.54"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-86.0","spread":"0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-20.1","spread":"31.24"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in the Disability Index of the Health Assessment Questionaire (DI-HAQ, a Component of the American College of Rheumatology (ACR) Criteria by Visit","description":"Mean change from Baseline in DI-HAQ overall score (includes 20 questions assessing physical function in 8 domains - dressing, rising, eating, walking, hygiene, reach, grip, and usual activities). Each question is on a scale of 0-3 mm to measure the ability to perform certain activities (0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty, and 3 = unable to do so), a component of the ACR criteria by visit. DI-HAQ is derived based on the mean of individual responses not the total of individual questions","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":"0.75"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"0.49"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"0.53"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"0.51"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"0.53"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"0.54"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"0.56"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"0.53"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"0.58"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"0.56"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"0.57"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"0.52"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"0.59"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"0.58"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"0.55"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"0.62"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"0.58"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"0.57"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"0.58"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"0.56"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"0.59"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"0.55"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"0.48"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.4","spread":"0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"0.62"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in C-reactive Protein (CRP), a Component of the American College of Rheumatology (ACR) Criteria by Visit","description":"Mean change from Baseline in CRP (mg/dL), a component of the ACR criteria by visit. For M02-575 completers, the Baseline for all efficacy analyses was defined as the Week 0 \\[before dosing\\] of the M02-575 study; for the M02-575 rescue arm, the Baseline was defined as the Week 0 \\[before dosing\\] of the M03-651 study.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.7","spread":"3.30"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.2","spread":"3.02"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.7","spread":"3.38"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.6","spread":"3.69"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.5","spread":"3.33"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.6","spread":"3.58"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.8","spread":"3.60"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.9","spread":"3.51"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.2","spread":"3.55"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.3","spread":"3.66"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.5","spread":"3.46"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.4","spread":"3.77"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.9","spread":"3.90"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.3","spread":"3.59"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.1","spread":"3.63"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.7","spread":"4.02"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.3","spread":"3.45"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.3","spread":"3.37"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.5","spread":"3.57"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.4","spread":"3.89"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.2","spread":"4.55"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.2","spread":"4.21"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.4","spread":"6.38"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.0","spread":"0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.7","spread":"4.01"}]}]}]},{"type":"SECONDARY","title":"Presence of Morning Stiffness","description":"The number of subjects with morning stiffness at each visit. For M02-575 completers, the Baseline for all efficacy analyses was defined as the Week 0 \\[before dosing\\] of the M02-575 study; for the M02-575 rescue arm, the Baseline was defined as the Week 0 \\[before dosing\\] of the M03-651 study.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"182","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"173","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"168","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"167","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"154","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"148","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"138","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"106","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"141","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in the Duration (Minutes) of Morning Stiffness by Visit","description":"Mean change (minutes) from Baseline in morning stiffness (duration). For M02-575 completers, the Baseline for all efficacy analyses was defined as the Week 0 \\[before dosing\\] of the M02-575 study; for the M02-575 rescue arm, the Baseline was defined as the Week 0 \\[before dosing\\] of the M03-651 study.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"221.8","spread":"374.72"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-48.9","spread":"292.93"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-64.2","spread":"307.03"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-69.4","spread":"387.21"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-79.7","spread":"348.20"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-64.0","spread":"338.37"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-87.9","spread":"318.04"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-104.9","spread":"293.66"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-79.9","spread":"287.89"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-86.5","spread":"281.83"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-95.0","spread":"363.90"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-86.4","spread":"247.30"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-30.5","spread":"145.23"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-95.6","spread":"248.27"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-97.4","spread":"263.44"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-94.8","spread":"278.36"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-116.9","spread":"279.96"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-34.2","spread":"372.50"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-46.3","spread":"169.08"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-138.0","spread":"338.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-98.8","spread":"139.98"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-47.7","spread":"113.65"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.0","spread":"0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-57.9","spread":"358.24"}]}]}]},{"type":"SECONDARY","title":"Presence of Rheumatoid Factor (RF)","description":"The number of subjects who were positive for rheumatoid factor (RF) at each visit. RF considered negative if \\<=20 IU/mL and positive if \\>20 IU/mL.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"248","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"191","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"142","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"250","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Rheumatoid Factor (IU/ML) by Visit","description":"Mean change from Baseline in RF (IU/mL). For M02-575 completers, the Baseline for all efficacy analyses was defined as the Week 0 \\[before dosing\\] of the M02-575 study; for the M02-575 rescue arm, the Baseline was defined as the Week 0 \\[before dosing\\] of the M03-651 study.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"293.7","spread":"412.95"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-37.6","spread":"303.19"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-82.1","spread":"322.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-104.2","spread":"286.58"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-59.7","spread":"445.83"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-101.0","spread":"344.41"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-111.1","spread":"374.58"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-139.1","spread":"357.30"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-143.0","spread":"428.18"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-76.0","spread":"128.47"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-55.9","spread":"338.06"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":111,"n":309},"commonTop":["Nasopharyngitis","Adverse drug reaction","DNA antibody positive","Constipation","Insomnia"]}}}